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Abstract: Anesthesia for percutaneous transluminal angioplasty (PTA) involves a high-risk
population having a broad spectrum of pain character and intensity. This study delved the anesthetic
efficacy of dexmedetomidine versus midazolam, when used with remifentanil. Seventy patients
scheduled for femoropopliteal PTA were randomized into two groups receiving either intermittent
midazolam boluses (0.03–0.05 mg/kg) (MR group) or dexmedetomidine 0.2–0.7 µg/kg/h after a
loading dose of 1.0 µg/kg for 10 min (DR group), both with remifentanil. The primary endpoint was
the patients’ satisfaction (1–5, 5; extremely satisfied). Secondary endpoints included postprocedural
pain scores (0–10, 10; worst imaginable pain) and adverse events. The satisfaction level of patients
was significantly greater in the DR group compared with the MR group (4.0 [3.0, 5.0] versus 4.0
[2.0, 5.0] p = 0.021). The number of patients having a postprocedural pain score of at least 3 was
significantly greater in the MR group compared with the DR group (10 [29%] versus 2 [6%], p = 0.013).
The number of patients with hypotensive episodes was higher in the DR group (5 [14.7%] versus 0,
p = 0.025), which could all be restored with ephedrine. The use of dexmedetomidine in conjunction
with remifentanil may be a safe option that provides excellent patient satisfaction while potentially
attenuating postprocedural pain.
Keywords: percutaneous transluminal angioplasty; dexmedetomidine; satisfaction
1. Introduction
Confronting an ageing society, the prevalence of peripheral artery disease (PAD) and its
related morbidities continue to escalate [1]. Accordingly, the need for a proper anesthetic care for
patients undergoing percutaneous transluminal angioplasty (PTA) is increasing [2]. Currently, many
cardiovascular procedures that require monitored anesthetic care (MAC) are performed using a
remifentanil-based regimen for its superb analgesic efficacy and pharmacokinetic advantage of rapid
elimination [3,4]. However, opioids inevitably accompany respiratory depression and do not provide
sedation [5,6]. On the other hand, sedatives such as midazolam or propofol have no analgesic effects,
and their combined use with opioids further increases the risk of respiratory compromise requiring
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advanced airway management [7]. In addition, anesthetic care for PTA can be complicated by the
following. First, by sharing same risk factors with cardiovascular diseases, patients with PAD exhibit a
2- to 6-times greater risk of cardiovascular events [1,8], comprising a high-risk population. Second,
patients with PAD present broad spectrums of pain intensity and character [1], not to mention that
endovascular ballooning elicits considerable ischemic pain. Moreover, pain may persist even after
24 h of revascularization, possibly due to oxidative stress and inflammatory response [9]. Thus,
validation of an anesthetic regimen that enables maintaining a fine balance between patients’ safety
and satisfaction would be of high priority.
Dexmedetomidine is a highly selective alpha 2 agonist that possess unique properties as it is
able to provide both sedation and analgesia whilst preserving the respiratory function [10]. Previous
studies showed its favorable effects on respiration and interventionists’ satisfaction in catheter ablation
for atrial fibrillation [4]. In terms of PTA, dexmedetomidine may also prove to be beneficial for post
reperfusion pain as it has been shown to exert anti-oxidant and anti-inflammatory effects in animal
models of ischemia-reperfusion injury [11,12], yet, no comprehensive evidence exists in that regard.
Thus, we hypothesized that the addition of dexmedetomidine to a remifentanil-based MAC regimen
for PTA would improve patients’ satisfaction without respiratory compromise and have the potential
of extended analgesic efficacy into the postprocedural period.
The primary aim of this randomized, controlled study was to compare the anesthetic efficacy
of dexmedetomidine versus midazolam in PTA by comparing the patients’ satisfaction. Secondary
endpoints were interventionists’ satisfaction, pain intensity and postprocedural analgesic requirements
up to 24 h after the procedure, and the occurrence of drug-related adverse events.
2. Methods
2.1. Study Population
The current trial was approved by the institutional review board of the Yonsei University Health
System, Seoul, South Korea and then enlisted in http://clinicaltrials.gov (NCT 02929095) and followed
CONsolidated Standards of Reporting Trials (CONSORT) 2010 guidelines. After acquiring informed
consent from each patient, 70 patients with American Society of Anesthesiologist physical status
I to III, aged 20–80 years, who underwent PTA for femoropopliteal lesions under MAC between
October 2016 and March 2018 were enrolled. We excluded patients with psychiatric disorder, cognitive
impairment, myocardial infarction and/or stroke, hepatic dysfunction, or congestive heart failure.
Patients were randomly and evenly assigned to either midazolam plus remifentanil (MR, n = 35) group
or dexmedetomidine plus remifentanil (DR, n = 35) group by a computerized randomization table.
Blinding of the group designation was maintained to the patients and the attending anesthesiologists
and interventionists, while the studied drugs were prepared by an anesthesia nurse who was not
involved in patient care or assessment.
2.2. Anesthetic and Procedural Management
After entering the hybrid operating theatre, ECG, non-invasive blood pressure, pulse-oximetry
(SaO2), and respiratory rate were monitored in all patients. Before starting MAC, all patients received
oxygen at 5 L/min through an oxygen mask. Then, MAC was initiated using either MR or DR regimen
and procedural draping and local anesthesia with 1% lidocaine to the ipsilateral and/or contralateral
inguinal area were followed after 10 min of commencing MAC.
MAC was provided to all patients as follows. In the MR group, 0.03–0.05 mg/kg of midazolam
was given as a bolus placement, while the patients in the DR group received same amount of 0.9%
saline. In the DR group, 1.0 µg/kg of dexmedetomidine bolus placement was done for 10 min using a
syringe pump, and then maintained until the end of the procedure at infusion rates of 0.2–0.7 µg/kg/h,
while the MR group received same infusions of 0.9% saline. Dose adjustments were done to target the
Ramsay sedation score of 2 to 4 (1 = anxious and agitated, restless or both; 2 = co-operative, oriented
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and tranquil; 3 = response to commands only; 4 = brisk response and 5 = sluggish response to light
glabellar tap or loud auditory stimulus; 6 = no response to stimulation) [13].
In all patients, continuous infusion of remifentanil at 1.2 µg/kg/h remifentanil using a syringe
pump was started concomitantly with the bolus placement of midazolam or dexmedetomidine. The
infusion rate of remifentanil was adjusted according to the pain score evaluation (11-point numeric
rating scale; 0 = no pain to 10 = worst imaginable pain). The remifentanil infusion rate was increased
by 0.6 µg/kg/h and up to 7.2 µg/kg/h to maintain the pain score ≤3. Remifentanil infusion rate was
decreased by 0.6 µg/kg/h until reaching 0.6 µg/kg/h when the pain score was between 0 and 1.
If hypotension occurred (mean arterial pressure < 60 mmHg), 4–8 mg of ephedrine was given
intravenously. If bradycardia (heart rate < 45 bpm) occurred, 0.1–0.2 mg of glycopyrrolate was given
intravenously. If bradycardia persisted, 0.5 mg of atropine was given intravenously. If respiratory
depression (respiratory rate < 10/min) and/or hypoxia (SaO2 < 90%) occurred, patients were given a
verbal awakening stimulation (calling their name) followed by a gentle squeeze at the trapezius muscle
if unresponsive. If respiratory depression persisted despite these stimulations, the rate of remifentanil
infusion was reduced by 0.6 µg/kg/h and head extension with or without jaw thrust was performed,
while preparing for further advanced airway management.
PTA was considered successful when the degree of residual stenosis was below 30% without any
dissection compromising the flow.
In the postprocedural period, patients were given acetaminophen, tramadol, meperidine, or
oxycodone as rescue analgesics upon their request or when the pain score exceeded 4. The choice of
the rescue analgesic was done at the discretion of the attending physician at the ward. In order to
compare the doses, substitution was made with equipotent doses of morphine.
2.3. Primary Endpoint and Assessment
The primary endpoint of the current study was to compare the anesthetic efficacy between DR
and MR in terms of patients’ satisfaction about the MAC. At the post-anesthesia care unit (PACU), the
patients were asked to choose their satisfaction score about their given MAC using a 5-point numerical
rating scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = extremely
satisfied) before being transferred to the general ward.
2.4. Secondary Endpoints and Assessments
After the end of procedure, the interventionists were asked to choose their satisfaction score
using the same 5-point numeric rating scale. In the PACU before being transferred to the general
ward, patients were asked for the overall pain score during the procedure using the above described
11-point numeric rating scale. They were also asked for the overall pain score during the 24 h of
the post-procedural period. Patients were also asked for the frequency of having a pain score ≥3
during the study period. The number of patients requiring rescue analgesics, and the total amount of
analgesics administered to the patients in morphine equivalent dose was recorded.
2.5. Statistical Analysis
Sample size calculation was calculated based on the patients’ satisfaction score. In a previous
study, the level of satisfaction by MR regimen in catheter ablation for atrial fibrillation was 2.9 ± 0.6 [4].
Assuming that the use of dexmedetomidine instead of midazolam can enhance the satisfaction level
by 0.5 or more, the estimated number of patients in each group was 31 (α = 0.05 and power = 0.9).
Accounting for a dropout rate of 10%, we decided to enroll 35 patients in each group.
All statistical analyses were performed with the SAS 9.4 and Rx64 program. Intergroup
comparisons of satisfaction and pain scores were done by Mann-Whitney U test. Continuous variables
were assessed for their distribution (Shapiro-Wilk test). Intergroup comparison of other variables that
showed normal distribution were tested using the independent t-test (mean ± standard deviation
[SD]). Skewed data were tested using Mann-Whitney U test (median [interquartile range]). Intergroup
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comparisons of categorical variables were tested using Chi-square test (n [%]). For pain scores that
were assessed at 3 time points, post hoc Bonferroni correction was applied. Thus, the p values for the
pain scores were considered statistically significant when <0.017. Otherwise, p < 0.05 was considered
statistically significant.
3. Results
A total of 105 patients were screened, and 70 among them were enrolled and evenly randomized
into either the MR or DR group. There was one dropout among the 70 enrolled subjects (Figure 1).
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Table 1. Patients’ Characteristics and procedural data.
Midazolam (n = 35) Dexmedetomidine (n = 34)
Age (years) 64.7 ± 12.5 64.1 ± 11.5
Sex (M/F) 34/1 27/7
Body surface area (m2) 1.75 ± 0.16 1.71 ± 1.9
Hypertension 25 (71.4) 20 (58.8)
Diabetes mellitus 19 (54.3) 16 (47.1)
Coronary artery disease 13 (37.1) 11 (32.4)
End-stage renal disease 1 (2.9) 2 (5.9)
Cerebrovascular accident 3 (8.6) 5 (14.7)
Medications
Aspirin 30 (85.7) 23 (67.6)
Thienopyridine 26 (74.3) 21 (61.8)
Cilostazol 8 (22.9) 3 (8.8)
Warfarin 3 (8.6) 1 (2.9)
Statin 20 (57.1) 19 (55.9)
Beta-blocker 3 (8.6) 3 (8.8)
Rutherford category
1 1 (2.9) 1 (2.9)
2 4 (11.4) 5 (14.7)
3 18 (51.4) 17 (50.0)
4 5 (14.3) 8 (23.5)
5 4 (11.4) 1 (2.9)
6 3 (8.6) 2 (5.9)
Current smoker, n (%) 8 (22.9) 6 (20.0)
Procedure time (min) 59.7 ± 37.8 53.7 ± 31.4
Intraoperative medication
Remifentanil (µg/kg/h) 0.72 [0.50, 1.31] 0.72 [0.49, 1.06]
Midazolam (µg/kg/h) 20.51 [13.79, 44.44] 0 [0, 0]
Dexmedetomidine (µg/kg/h) 0 [0, 0] 51.00 [37.87, 74.40]
Data are displayed in mean ± SD, or n (%).
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Table 2. Primary and secondary endpoints.
Midazolam (n = 35) Dexmedetomidine (n = 34) p-Value
Primary endpoint
Patients’ satisfaction 4.0 [3.0,4.0] 4.0 [4.0,5.0] 0.021 *
Secondary endpoints
Interventionists’ satisfaction 4.0 [4.0,4.5] 4.0 [3.5,4.0] 0.860
Pain scores
Baseline 2 [1,3] 2 [2,4] 0.734
Procedural 3 [0,4] 0.5 [0,4] 0.192
Post-procedural 24 h 0 [0,3] 0 [0,1] 0.213
Pain score ≥3 10 (28.6) 2 (5.9) 0.013 *
Rescue analgesics 13 (37.1) 13 (38.2) 0.925
Rescue morphine dose (mg) 10.0 [5.5,18.2] 6.6 [5.0,10.0] 0.062
Adverse events
Bradycardia 0 0 1.000
Hypotension 0 5 (14.7%) 0.025 *
Hypoxia 1 (2.9%) 0 1.000
Nausea 0 1 (2.9%) 0.310
Data are displayed in mean ± SD, n (%), or median (interquartile range). Satisfaction score was assessed using a
5-point numerical scale (1 = extremely dissatisfied~5 = extremely satisfied). * = p < 0.05. Pain score was assessed
using an 11-point numeric scale (0 = no pain~10 = worst imaginable pain). Rescue analgesic dose was calculated as
morphine equivalent dose. * = p < 0.05.
Hemodynamic data including heart rate and mean arterial pressure, and SaO2 were all within
clinically acceptable ranges and showed no intergroup differences throughout the procedure (Figure 3).
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In terms of drug-related adverse events, incidences of bradycardia and hypoxia were not different
between the groups, while the number of patients with 1 or more hypotensive episodes was higher
in the DR group compared with the R group, which could all b managed by a single bol s of
intravenous ephedrine administration (Table 2).
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Pain scores and the frequency of rescue analgesic requirement up to 24 h after the procedure were
similar between the groups. However, the number of patients having a pain score of at least 3 was
significantly greater in the MR group compared with the DR group (10 [29%] versus 2 [6%], p = 0.013),
while the total amount of administered rescue analgesics in morphine equivalent dose showed a trend
towards being lower in the DR group compared with the MR group (6.6 [5.0, 10.0] mg versus 10.0 mg
[5.5, 18.2] mg, p = 0.062) (Table 2).
4. Discussion
Anesthetic care for PTA can be challenging as patients with PAD comprise a high-risk group for
cardiovascular events [14,15]. Thus, emphasis should be given to prevent anxiety or pain responses that
cause maladaptive sympathetic activation during PTA. Also, successful PTA requires immobilization
while confronting the fact that the patients already exhibit a broad spectrum of pain in addition to the
ischemic pain elicited by intermittent ballooning.
For MAC during cardiovascular procedures, continuous infusion of remifentanil has become
the mainstay of anesthesia with the intermittent use of sedatives as necessary. Opioids have their
advantages in that they are potent analgesics able to cover diverse pain characters and they lack
direct myocardial depressant effects except for their central vagotonic influence [16]. However, in
patients with rigorous pain, increasing the dose of remifentanil may not be feasible as opioids cause
respiratory depression, which could be troublesome in a supine position with an increased risk
of airway-compromise [5]. On the other hand, increasing the dose of sedatives may not suffice as
the commonly used sedatives lack analgesic effects, and possibly also hyperalgesia lowering the pain
thresholds [17], on top of increasing the risk of respiratory depression. Thus, finding an anesthetic regimen
that provides adequate sedation without suppressing respiration would be of high priority for PTA.
Dexmedetomidine is a potent and selective alpha 2 agonist exerting sedative and analgesic
effects at the same time without compromising respiration. Accordingly, emerging evidence supports
its beneficial influence in critical care and MAC involving conscious sedation for cardiovascular
procedures [4], while its anesthetic efficacy in PTA has never been validated heretofore. Moreover,
nociceptive pain with PAD involves intermittent episodes of ischemia-reperfusion and its chronic
manifestation has been shown to result in complex neuropathic pain as well [18]. Importantly,
even successful PTA has been shown to elicit significant postprocedural pain related to reperfusion
and oxidative stress [9,19]. Experimentally, dexmedetomidine has been shown to be effective in
neuropathic pain through the inhibition of IL-6 and TNF-a [20]. Also, dexmedetomidine has been
shown to attenuate oxidative and inflammatory stress responses related to ischemia-reperfusion [11,12].
Moreover, the EEG patterns observed during dexmedetomidine infusion more closely resembles those
of the natural sleep as opposed to other anesthetics [21], which may be favorable in terms of the sleep
quality. Thus, we hypothesized that the use of dexmedetomidine in PTA would not only improve
patients’ satisfaction during the procedure, but also exert beneficial influence in postprocedural pain.
As our results indicate, patients receiving dexmedetomidine were more satisfied with their
anesthetic care than those receiving midazolam with none of the patients in the DR group reporting
a satisfaction score of less than 3 (from a 5-point numeric scale with 5 being extremely satisfied)
confirming our primary hypothesis. This beneficial effect of dexmedetomidine was even more evident
in patients with considerable resting pain (Rutherford category ≥4). In terms of its efficacy on pain
scores, we could only observe trends towards lower procedural and postprocedural pain scores in
the DR group compared with the MR group. Interestingly, there were a significantly lower number
of patients in the DR group who experienced a significant postprocedural pain (pain scores of ≥3)
than the MR group, despite receiving a lower amount of rescue analgesics. Thus, per our hypothesis,
the experimentally proven anti-inflammatory property of dexmedetomidine attenuating oxidative
stress may have been responsible for the reduced incidence of intense pain after reperfusion in the
current study. Also, concerns have been raised regarding a potential hyperalgesic phenomenon
after discontinuation of remifentanil infusion that is not clearly understood [22]. Dexmedetomidine
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may also attenuate the hyperalgesic response after the discontinuation of remifentanil infusion by
modulating spinal cord N-methyl-D-aspartate receptor activation via suppression of NR2B subunit
phosphorylation [23], which may have contributed to the attenuated postprocedural pain.
In terms of drug-related adverse events, use of dexmedetomidine was associated with more
frequent episodes of hypotension, which could all be rapidly restored by a single ephedrine bolus.
This result agrees with our previous report involving patients undergoing catheter ablation of atrial
fibrillation [4]. By being a sympatholytic, dexmedetomidine’s potential to cause hypotension and
bradycardia has been well acknowledged. Yet, its biphasic hemodynamic response usually shows
an initial increase by mean arterial pressure with subsequent bradycardia and return to baseline
hemodynamic after stabilization [24]. As with our previous study [4], the chosen dose range of our
study seems to be safe in terms of mean arterial pressure and heart rate, as they were similar between
the studied drugs, and showed that the hypotensive events could all be rapidly corrected.
In terms of opioid sparing effect and respiratory function, we could not observe any significant
favorable influence of dexmedetomidine over the conventional use of midazolam, which may be
attributable to the following. The chosen MR regimen has been used and adjusted in our institution
over the past 5 years for PTA to provide safe conscious sedation, which yielded acceptable patient
satisfaction as well.
The limitations of the current study are as follows. Although there are solid experimental
backgrounds, we did not measure markers of oxidative stress or inflammation, and thus, we can
only speculate about the favorable influence of dexmedetomidine on post-reperfusion pain. Also, the
sample size may be insufficient for validating our secondary endpoints, especially in terms of pain
scores as they showed only statistical trends towards being lower in the DR group. Lastly, due to the
nature of the disease, the inclusion of male patients was predominant, limiting the extrapolation of
these results to female patients.
In conclusion, MAC for a high-risk group requires special attention balancing the safety and the
patients’ satisfaction. Also, a proper anesthetic regimen should be tailored to cover the disease- and
procedure-specific pain characteristics that are unique to patients with PAD undergoing PTA. In line
with these needs, the current study provides primary evidence that the use of dexmedetomidine in
conjunction with remifentanil may be a safe option that provides excellent patients’ satisfaction while
potentially attenuating postprocedural pain as well.
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